Peru took a historic step in prevention of cervical cancer. He Ministry of Health (Minsa) announced the incorporation of the Nonavalent vaccine against human papillomavirus (HPV) to the National Vaccination Schemeofficial measure through the Ministerial Resolution No. 440-2025/MINSApublished on July 18.
This new dose protects against Nine HPV variantsresponsible for 90 % of cervical cancer cases and other related tumors. From now on, girls, boys and adolescents up to 18 years They will be able to access the vaccine for free in Health Centers, Colleges and Community Campaigns.
A key decision to the main cause of cancer death
Cervical cancer continues to be the First cause of cancer death in Peruvian womeneven surpassing breast cancer. According to the study Reduce the equity gap: oncological attention for women in Peru De Economist Impact, in 2022 they were recorded 2,545 deaths from cervical cancerin front of 1,951 by breast cancer.
The disease more frequently affects young women, low -income and residents in rural areas or indigenous communitieswhere access to vaccination is usually more limited.
Safe and sustainable access
Peru will guarantee the purchase of the vaccine through ROTATORY OPS FUNDwhich allows it to obtain it at a lower cost and with safe supply. All doses have the quality certification of the WHO.
Karla Ruiz de Castilla, director of the Patient Association Esperantrahighlighted:
“This decision of the Minsa marks a fundamental advance to reduce inequality in oncological prevention. Ensure that the vaccine reaches those who need it most is key to saving lives.”
How to access vaccination
- Target population: Girls, boys and adolescents until 18 years.
- Application points: Health centers, colleges and community campaigns.
- Recommendation: Carry DNI and vaccination card for dose registration.
With this incorporation, the country strengthens its strategy of Primary cervical cancer preventionadvancing towards more equitable coverage and saving thousands of lives in the future.
